C Kazda

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
    Christof Kazda
    Lilly Deutschland GmbH, Bad Homburg, Germany
    J Diabetes Complications 20:145-52. 2006
  2. doi request reprint Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
    Christof M Kazda
    Eli Lilly and Company, Suresnes, France
    Diabetes Care 39:1241-9. 2016
  3. doi request reprint The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics
    C Kazda
    Lilly Deutschland GmbH, 61352 Bad Homburg, Germany
    Diabetes Obes Metab 11:1131-7. 2009
  4. ncbi request reprint Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Parcusstrasse 8, Mainz D 55116, Germany
    J Diabetes Complications 19:128-32. 2005

Detail Information

Publications4

  1. ncbi request reprint Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
    Christof Kazda
    Lilly Deutschland GmbH, Bad Homburg, Germany
    J Diabetes Complications 20:145-52. 2006
    ..To compare the effects of prandial insulin therapy focusing on postprandial glucose control vs. basal insulin therapy focusing on fasting glucose control in patients with type 2 diabetes...
  2. doi request reprint Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
    Christof M Kazda
    Eli Lilly and Company, Suresnes, France
    Diabetes Care 39:1241-9. 2016
    ..LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type 2 diabetes...
  3. doi request reprint The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics
    C Kazda
    Lilly Deutschland GmbH, 61352 Bad Homburg, Germany
    Diabetes Obes Metab 11:1131-7. 2009
    ..To describe the rationale for the European Exenatide (EUREXA) clinical study and describe the characteristics of the patient cohort...
  4. ncbi request reprint Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Parcusstrasse 8, Mainz D 55116, Germany
    J Diabetes Complications 19:128-32. 2005
    ..0 (19.0-49.3) vs. 20.9 (9.7-26.1) AU, P=.0001]. Postprandial microvascular blood flow is disturbed in patients with Type 1 diabetes. Improvement of postprandial metabolic control was found to improve postprandial microvascular function...